For information and orders please call +44 1200 760076, or you can request a callback by clicking here.
Available 9am to 5pm UK, Monday to Friday. If calling outside business hours please leave a message and we will call you back.

Independent ion eXtra™ Trial Summary

An independent study of the impact of electrolyte balance intervention on 74 subjects 39 – 78 years of age who were pre-hypertensive or hypertensive through the administration of the smart active signaling capsule, ion eXtra™ (trade name). The average age of the subjects taking part in the trial was 63 years.

The objective of the study was to ascertain whether electrolyte balance intervention significantly reduces constant resting blood pressure in hypertensive subjects.

The trial results show that every participant in the trial benefited from the single course of ion eXtra™ administered and, on average, resting blood pressure decreased from 165/87 to 141/71.

Before the trial started, 4 subjects were pre-hypertensive, 24 were stage 1 hypertensive, 37 were stage 2 and 9 were critical.

At the conclusion of the trial, 39 were pre-hypertensive, 30 were Stage 1, 5 were Stage 2 and none were critical. 21 subjects experienced a fall in systolic pressure of more than 30 mmHg and the greatest drop in diastolic pressure was 20 mmHg.

The trial was carried out by independent analysts appointed by Scientific Health Inc, an American company, as part of their due diligence process before contracting to distribute the product internationally. The analysts concluded that the results of the trial supported the manufacturer’s claim that ion eXtra™ significantly reduced blood pressure in cases of hypertension.

Click here to download a copy of the complete report (requires Adobe Acrobat Reader).

All rights reserved. Terms and Conditions